{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:49:47Z","timestamp":1774532987338,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,18]]},"DOI":"10.7759\/cureus.48994","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:57:48Z","timestamp":1700308668000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population"],"prefix":"10.7759","author":[{"given":"Amanullah","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shajee Ahmad","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bikha","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jibran Umar Ayub","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Raja Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Rehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Zia ul Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Kumar Seetlani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayyab S","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masood","family":"Khoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riaz","family":"Hussain Khokhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaheer","family":"Hussain Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajid","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samiullah","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Khan Khattak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Qayoom","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaheen","family":"Bhatty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idress","family":"Shani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeta","family":"Maheshwary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304269","article-title":"Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"63","author":"El-Serag HB","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014, 63:871-80. 10.1136\/gutjnl-2012-304269","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X166817","article-title":"The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease","volume":"10","author":"Fass R","year":"2017","unstructured":"Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017, 10:243-51. 10.1177\/1756283X166817","journal-title":"Therap Adv Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis","volume":"153","author":"Hooi JK","year":"2017","unstructured":"Hooi JK, Lai WY, Ng WK, et al.. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017, 153:420-9. 10.1053\/j.gastro.2017.04.022","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2019.09.882","article-title":"Factors influencing quality of life in patients with gastroesophageal reflux disease in a tertiary care hospital in Pakistan","volume":"29","author":"Lail G","year":"2019","unstructured":"Lail G, Hanif FM, Lail A, Haque MM, Tasneem AA, Luck NH. Factors influencing quality of life in patients with gastroesophageal reflux disease in a tertiary care hospital in Pakistan. J Coll Physicians Surg Pak. 2019, 29:882-5. 10.29271\/jcpsp.2019.09.882","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01351.x","article-title":"Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease","volume":"16","author":"Spechler SJ","year":"2002","unstructured":"Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002, 16:1795-800. 10.1046\/j.1365-2036.2002.01351.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2017.07.001","article-title":"Gastroesophageal reflux disease","volume":"44","author":"Kellerman R","year":"2017","unstructured":"Kellerman R, Kintanar T. Gastroesophageal reflux disease. Prim Care. 2017, 44:561-73. 10.1016\/j.pop.2017.07.001","journal-title":"Prim Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05912.x","article-title":"Gastroesophageal reflux disease--should we adopt a new conceptual framework?","volume":"97","author":"Fass R","year":"2002","unstructured":"Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework?. Am J Gastroenterol. 2002, 97:1901-9. 10.1111\/j.1572-0241.2002.05912.x","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225631.07039.6d","article-title":"Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics","volume":"41","author":"Fass R","year":"2007","unstructured":"Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007, 41:131-7. 10.1097\/01.mcg.0000225631.07039.6d","journal-title":"J Clin Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/00365520410003498","article-title":"Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex","volume":"39","author":"Nilsson M","year":"2004","unstructured":"Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex. Scand J Gastroenterol. 2004, 39:1040-5. 10.1080\/00365520410003498","journal-title":"Scand J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e158","article-title":"Gender specific differences in prevalence and risk factors for gastro-esophageal reflux disease","volume":"34","author":"Kim SY","year":"2019","unstructured":"Kim SY, Jung HK, Lim J, et al.. Gender specific differences in prevalence and risk factors for gastro-esophageal reflux disease. J Korean Med Sci. 2019, 34:e158. 10.3346\/jkms.2019.34.e158","journal-title":"J Korean Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5056\/jnm16138","article-title":"Sex and gender differences in gastroesophageal reflux disease","volume":"22","author":"Kim YS","year":"2016","unstructured":"Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2016, 22:575-88. 10.5056\/jnm16138","journal-title":"J Neurogastroenterol Motil"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v6.i8.176","article-title":"Risk factors for gastroesophageal reflux disease and analysis of genetic contributors","volume":"6","author":"Argyrou A","year":"2018","unstructured":"Argyrou A, Legaki E, Koutserimpas C, Gazouli M, Papaconstantinou I, Gkiokas G, Karamanolis G. Risk factors for gastroesophageal reflux disease and analysis of genetic contributors. World J Clin Cases. 2018, 6:176-82. 10.12998\/wjcc.v6.i8.176","journal-title":"World J Clin Cases"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-3-200508020-00006","article-title":"Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications","volume":"143","author":"Hampel H","year":"2005","unstructured":"Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005, 143:199-211. 10.7326\/0003-4819-143-3-200508020-00006","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304189","article-title":"Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study","volume":"63","author":"El-Serag HB","year":"2014","unstructured":"El-Serag HB, Hashmi A, Garcia J, et al.. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut. 2014, 63:220-9. 10.1136\/gutjnl-2012-304189","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis","volume":"67","author":"Eusebi LH","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018, 67:430-40. 10.1136\/gutjnl-2016-313589","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz PO","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022, 117:27-56. 10.14309\/ajg.0000000000001538","journal-title":"Am J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-7-200404060-00011","article-title":"Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics","volume":"140","author":"Numans ME","year":"2004","unstructured":"Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004, 140:518-27. 10.7326\/0003-4819-140-7-200404060-00011","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054391","article-title":"Body-mass index and symptoms of gastroesophageal reflux in women","volume":"354","author":"Jacobson BC","year":"2006","unstructured":"Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006, 354:2340-8. 10.1056\/NEJMoa054391","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection--the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner P","year":"2012","unstructured":"Malfertheiner P, Megraud F, O'Morain CA, et al.. Management of Helicobacter pylori infection--the Maastricht IV\/Florence Consensus Report. Gut. 2012, 61:646-64. 10.1136\/gutjnl-2012-302084","journal-title":"Gut"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"American College of Gastroenterology guideline on the management of Helicobacter pylori infection","volume":"102","author":"Chey WD","year":"2007","unstructured":"Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007, 102:1808-25. 10.1111\/j.1572-0241.2007.01393.x","journal-title":"Am J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung I","year":"2016","unstructured":"Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016, 43:514-33. 10.1111\/apt.13497","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i9.2786","article-title":"Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study","volume":"21","author":"Zhang YX","year":"2015","unstructured":"Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015, 21:2786-92. 10.3748\/wjg.v21.i9.2786","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16668093","article-title":"Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence","volume":"9","author":"Akazawa Y","year":"2016","unstructured":"Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016, 9:845-52. 10.1177\/1756283X16668093","journal-title":"Therap Adv Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study","volume":"42","author":"Sakurai Y","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015, 42:719-30. 10.1111\/apt.13325","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising Tak-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects","volume":"6","author":"Sakurai Y","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising Tak-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol. 2015, 6:e94. 10.1038\/ctg.2015.18","journal-title":"Clin Transl Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen H","year":"2016","unstructured":"Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016, 55:409-18. 10.1007\/s40262-015-0326-7","journal-title":"Clin Pharmacokinet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12438","article-title":"Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?","volume":"22","author":"Dong SQ","year":"2017","unstructured":"Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?. Helicobacter. 2017, 22:10.1111\/hel.12438","journal-title":"Helicobacter"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication","volume":"46","author":"Jung YS","year":"2017","unstructured":"Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017, 46:106-14. 10.1111\/apt.14130","journal-title":"Aliment Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12495","article-title":"Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori","volume":"23","author":"Li M","year":"2018","unstructured":"Li M, Oshima T, Horikawa T, et al.. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018, 23:e12495. 10.1111\/hel.12495","journal-title":"Helicobacter"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04142.x","article-title":"Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care","volume":"30","author":"Jones R","year":"2009","unstructured":"Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, Lind T. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009, 30:1030-8. 10.1111\/j.1365-2036.2009.04142.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12204","article-title":"Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease","volume":"37","author":"Jonasson C","year":"2013","unstructured":"Jonasson C, Wernersson B, Hoff DA, Hatlebakk JG. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013, 37:564-72. 10.1111\/apt.12204","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0492-17","article-title":"Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease","volume":"57","author":"Niikura R","year":"2018","unstructured":"Niikura R, Yamada A, Hirata Y, et al.. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med. 2018, 57:2443-50. 10.2169\/internalmedicine.0492-17","journal-title":"Intern Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05092.x","article-title":"Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD","volume":"35","author":"Jonasson C","year":"2012","unstructured":"Jonasson C, Moum B, Bang C, Andersen KR, Hatlebakk JG. Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD. Aliment Pharmacol Ther. 2012, 35:1290-300. 10.1111\/j.1365-2036.2012.05092.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.734","article-title":"Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis","volume":"105","author":"Yaghoobi M","year":"2010","unstructured":"Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010, 105:1007-13; quiz 1006, 1014. 10.1038\/ajg.2009.734","journal-title":"Am J Gastroenterol"},{"key":"ref35","article-title":"Effect of HP eradication on the development of gastroesophageal reflux disease: results of the prospective study (Article in Russian)","author":"Pasechnikov VD","year":"20113","unstructured":"Pasechnikov VD, Chotchaeva AR, Pasechnikov DV. Effect of HP eradication on the development of gastroesophageal reflux disease: results of the prospective study (Article in Russian). Eksp Klin Gastroenterol. 20113, 105-10.","journal-title":"Eksp Klin Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2011.648955","article-title":"Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials","volume":"47","author":"Saad AM","year":"2012","unstructured":"Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2012, 47:129-35. 10.3109\/00365521.2011.648955","journal-title":"Scand J Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.29.4.466","article-title":"Prevalence and risk factors for reflux esophagitis in patients with chronic obstructive pulmonary disease","volume":"29","author":"Kim SW","year":"2014","unstructured":"Kim SW, Lee JH, Sim YS, Ryu YJ, Chang JH. Prevalence and risk factors for reflux esophagitis in patients with chronic obstructive pulmonary disease. Korean J Intern Med. 2014, 29:466-73. 10.3904\/kjim.2014.29.4.466","journal-title":"Korean J Intern Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida K","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al.. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016, 43:240-51. 10.1111\/apt.13461","journal-title":"Aliment Pharmacol Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3892\/br.2017.947","article-title":"Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease","volume":"7","author":"Shinozaki S","year":"2017","unstructured":"Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Kobayashi Y, Lefor AK, Yamamoto H. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2017, 7:231-5. 10.3892\/br.2017.947","journal-title":"Biomed Rep"},{"key":"ref40","article-title":"Risk factors and prescription patterns of gastroesophageal reflux disease: HEAL study in Pakistan","volume":"64","author":"Butt AK","year":"2014","unstructured":"Butt AK, Hashemy I. Risk factors and prescription patterns of gastroesophageal reflux disease: HEAL study in Pakistan. J Pak Med Assoc. 2014, 64:751-7.","journal-title":"J Pak Med Assoc"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i41.5486","article-title":"Risk factors of gastroesophageal reflux disease in Shiraz, southern Iran","volume":"13","author":"Saberi-Firoozi M","year":"2007","unstructured":"Saberi-Firoozi M, Khademolhosseini F, Yousefi M, Mehrabani D, Zare N, Heydari ST. Risk factors of gastroesophageal reflux disease in Shiraz, southern Iran. World J Gastroenterol. 2007, 13:5486-91. 10.3748\/wjg.v13.i41.5486","journal-title":"World J Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02426.x","article-title":"Risk factors for gastro-oesophageal reflux disease symptoms: a community study","volume":"21","author":"Mohammed I","year":"2005","unstructured":"Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther. 2005, 21:821-7. 10.1111\/j.1365-2036.2005.02426.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S206995","article-title":"Gastro-oesophageal reflux disease symptoms and associated risk factors among medical students, Saudi Arabia","volume":"12","author":"Atta MM","year":"2019","unstructured":"Atta MM, Sayed MH, Zayed MA, Alsulami SA, Al-Maghrabi AT, Kelantan AY. Gastro-oesophageal reflux disease symptoms and associated risk factors among medical students, Saudi Arabia. Int J Gen Med. 2019, 12:293-8. 10.2147\/IJGM.S206995","journal-title":"Int J Gen Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.38.4.5436","article-title":"Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: a randomized control trial","volume":"38","author":"Zuberi BF","year":"2022","unstructured":"Zuberi BF, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A. Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: a randomized control trial. Pak J Med Sci. 2022, 38:965-9. 10.12669\/pjms.38.4.5436","journal-title":"Pak J Med Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu QJ","year":"2019","unstructured":"Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019, 2019:9781212. 10.1155\/2019\/9781212","journal-title":"Biomed Res Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184544-real-world-evidence-to-evaluate-the-efficacy-and-safety-of-vonoprazan-in-gastrointestinal-disorders-in-the-pakistani-population","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:09Z","timestamp":1707509169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184544-real-world-evidence-to-evaluate-the-efficacy-and-safety-of-vonoprazan-in-gastrointestinal-disorders-in-the-pakistani-population"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.48994","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,18]]}}}